Want to see TSE:LOVE full AI Analyst Report?
Total Valuation
Cannara Biotech has a market cap or net worth of C$183.73M. The enterprise value is C$183.06.
Market CapC$183.73M
Enterprise ValueC$183.06
Share Statistics
Cannara Biotech has 98,782,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,782,150
Owned by Insiders75.64%
Owned by Institutions―
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.86%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.86%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee237.43K
Profits Per Employee28.93K
Employee Count452
Asset Turnover0.64
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Cannara Biotech is 17.2. Cannara Biotech’s PEG ratio is 0.13.
PE Ratio17.2
PS Ratio1.57
PB Ratio1.64
Price to Fair Value1.64
Price to FCF12.31
Price to Operating Cash Flow9.95
PEG Ratio0.13
Income Statement
In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.
Revenue107.32M
Gross Profit47.22M
Operating Income22.20M
Pretax Income18.10M
Net Income13.08M
EBITDA28.18M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 18.46M and capital expenditures -13.72M, giving a free cash flow of 4.74M billion.
Operating Cash Flow18.46M
Free Cash Flow4.74M
Free Cash Flow per Share0.05
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-3.63%
50-Day Moving Average1.75
200-Day Moving Average1.77
Relative Strength Index (RSI)53.78
Average Volume (3m)45.69K
Important Dates
Cannara Biotech upcoming earnings date is Nov 24, 2026, Before Open (Confirmed).
Last Earnings DateJul 15, 2026
Next Earnings DateNov 24, 2026
Ex-Dividend Date―
Financial Position
Cannara Biotech as a current ratio of 2.40, with Debt / Equity ratio of 29.40%
Current Ratio2.40
Quick Ratio1.10
Debt to Market Cap0.24
Net Debt to EBITDA0.97
Interest Coverage Ratio5.10
Taxes
In the past 12 months, Cannara Biotech has paid 5.02M in taxes.
Income Tax5.02M
Effective Tax Rate0.28
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is 6.93, with an EV/FCF ratio of 14.31.
EV to Sales1.82
EV to EBITDA6.93
EV to Free Cash Flow14.31
EV to Operating Cash Flow9.76
Balance Sheet
Cannara Biotech has C$21.81M in cash and marketable securities with C$37.00M in debt, giving a net cash position of -C$15.19M billion.
Cash & Marketable SecuritiesC$21.81M
Total DebtC$37.00M
Net Cash-C$15.19M
Net Cash Per Share-C$0.15
Tangible Book Value Per ShareC$1.09
Margins
Gross margin is 26.30%, with operating margin of 20.68%, and net profit margin of 12.18%.
Gross Margin26.30%
Operating Margin20.68%
Pretax Margin16.86%
Net Profit Margin12.18%
EBITDA Margin26.26%
EBIT Margin20.29%
Analyst Forecast
The average price target for Cannara Biotech is C$3.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$3.33
Price Target Upside75.44% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast14.66%
EPS Growth Forecast-33.72%